Join the Abilify Maintena group to help and get support from people like you.
Abilify Maintena News
Long-Acting Injected Antipsychotics Help People With Schizophrenia Stay Out of Hospital
WEDNESDAY, Jan. 31, 2024 – For people with schizophrenia hospitalized after a psychotic episode, getting a long-acting antipsychotic injection works far better than pills to keep them from returning...
Antipsychotic Use Increased for Seniors With Alzheimer, Related Dementias
TUESDAY, Sept. 12, 2023 – Antipsychotics are more often used by older adults receiving home health care (HHC) services with Alzheimer disease and related dementias (ADRD) versus those without ADRD,...
Fewer Kids Are Being Prescribed Antipsychotic Meds
FRIDAY, July 7, 2023 – The use of antipsychotic medication in children is continuing to plummet, likely because of better policies and education, new research shows. The study found a 43% drop in...
FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
April 28, 2023 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA)...
FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication
November 13, 2017 – The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an...
Abilify Maintena (aripiprazole) for Extended-Release Injectable Suspension Approved by the U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder
Valby, Denmark and Tokyo, Japan, 28 July 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced Abilify Maintena® (aripiprazole) for extended-release ...
FDA Medwatch Alert: Aripiprazole (Abilify, Abilify Maintena, Aristada): Drug Safety Communication - FDA Warns About New Impulse-control Problems
ISSUE: FDA is warning that compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug aripiprazole (Abilify, Abilify...
FDA Approves Labeling Update Of Abilify Maintena for Acutely Relapsed Adults With Schizophrenia
Tokyo, Japan and Valby, Denmark – December 6, 2014 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced that the U.S. Food and Drug Administration (FDA) approved the lab...
FDA Approves Dual-Chamber Syringe for Abilify Maintena (aripiprazole) for Schizophrenia
Princeton, N.J. and Deerfield, Ill. – September 29, 2014 – Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration ...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Bipolar Disorder, Schizophrenia